Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiomolibdate choline - Alexion AstraZeneca Rare Disease/University of Michigan

Drug Profile

Tiomolibdate choline - Alexion AstraZeneca Rare Disease/University of Michigan

Alternative Names: ALXN-1840; ATN-224; Bis(choline)tetrathiomolybdate; Bis-choline tetrathiomolybdate; Decuprate; WTX-101

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Alexion AstraZeneca Rare Disease; Attenuon; Cancer Research UK
  • Class Antineoplastics; Heavy metals; Neuroprotectants; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis
  • Discontinued Breast cancer; Hepatolenticular degeneration; Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours

Most Recent Events

  • 30 Jun 2023 Alexion terminates phase-III trial in Hepatolenticular degeneration (In adolescents, In adults, In the elderly) in in United Kingdom, Turkey, Serbia, Taiwan, Singapore, Russia, Spain, Poland, New Zealand, South Korea, Japan, Israel, Hong Kong, Hungary, Germany, France, Denmark, Czech Republic, Canada, Belgium, Austria, Australia (PO) due to Sponsor decision to terminate the programm (NCT03403205)
  • 26 Jun 2023 Alexion terminates phase III trial in Hepatolenticular degeneration (In adolescents, In children) in France, Germany, Japan, South Korea, Poland, Spain, United Kingdom (PO) due to sponsor decision to terminate the program (NCT05047523)
  • 21 Jun 2023 Pharmacokinetics data from phase II trial in healthy volunteers presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top